K23 CA 85479/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Year	Number of Results
2004	1
2008	1
2012	1
2025	0

Page 1

Comparison of radiation dose estimation for myeloablative radioimmunotherapy for relapsed or recurrent mantle cell lymphoma using (131)I tositumomab to that of other types of non-Hodgkin's lymphoma.

Rajendran J, Gopal A, Durack L, Fisher D, Press O, Eary J. Rajendran J, et al. Cancer Biother Radiopharm. 2004 Dec;19(6):738-45. doi: 10.1089/cbr.2004.19.738. Cancer Biother Radiopharm. 2004. PMID: 15665621

131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes.

Hattori N, Gopal AK, Shields AT, Fisher DR, Gooley T, Pagel JM, Press OW, Rajendran JG. Hattori N, et al. Nucl Med Commun. 2012 Dec;33(12):1225-31. doi: 10.1097/MNM.0b013e328358d34b. Nucl Med Commun. 2012. PMID: 22955187 Free PMC article.

Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.

Rajendran JG, Gopal AK, Fisher DR, Durack LD, Gooley TA, Press OW. Rajendran JG, et al. J Nucl Med. 2008 May;49(5):837-44. doi: 10.2967/jnumed.107.043190. Epub 2008 Apr 15. J Nucl Med. 2008. PMID: 18413376 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year